Related Experiment Video
Updated: Feb 27, 2026
04:50
Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
1.2K
Prediction of Response to Targeted Treatment in Rheumatoid Arthritis.
1Rheumatology Department, Medical Center Slotervaart, Amsterdam, The Netherlands.
Mayo Clinic Proceedings
|July 10, 2017
Summary
Rheumatoid arthritis treatment needs personalization as biologic drugs vary in effectiveness. Exploring predictive markers aims for tailored therapies to achieve remission and improve patient quality of life.
Area of Science:
- Immunology
- Rheumatology
- Pharmacology
Background:
- Rheumatoid arthritis (RA) is a chronic autoimmune joint inflammation with diverse patient phenotypes.
- Despite advances like treat-to-target and biologic disease-modifying antirheumatic drugs (bDMARDs), not all patients achieve clinical remission.
- Individual responses to bDMARDs highlight variability in efficacy and immunological profiles.
Purpose of the Study:
- To address the need for personalized treatment strategies in rheumatoid arthritis.
- To explore predictive markers for optimizing bDMARD response and achieving rapid remission.
- To present a preliminary treatment algorithm based on current knowledge for RA management.
Main Methods:
- Review of latest explorative studies on predictive markers of treatment response in RA.
- Analysis of current knowledge regarding bDMARD efficacy and patient variability.
- Development of a preliminary treatment algorithm for personalized RA care.
Main Results:
- Significant variability exists in clinical response and efficacy of bDMARDs among RA patients.
- Explorative studies are identifying potential predictive markers for treatment outcomes.
- A personalized approach is crucial for maximizing remission rates and minimizing adverse effects.
Conclusions:
- Personalized treatment algorithms are essential for effective rheumatoid arthritis management.
- Identifying predictive markers will enable tailored bDMARD selection for individual patients.
- Achieving rapid remission through personalized therapy can prevent disability and enhance quality of life.
Related Concept Videos
01:21Rheumatic Heart Disease III: Medical Management
420
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
420
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
51
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
51
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
652
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
652
01:24T Cell Types and Functions
2.8K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.8K
01:11Genome-wide Association Studies-GWAS
15.9K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
15.9K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
604
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
604